UnicoCell's cell bank is the leading allogeneic cell bank of adipose stem cell source in Taiwan, built in accordance with ICH regulations (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). The stem cell product, ELIXCYTE®, cultured by the allogeneic cell bank has passed human clinical trials for knee osteoarthritis and chronic kidney disease.
UnicoCell's allogeneic stem cell bank is the best choice for cell starting material to be used for various indications in research units.
Through various MOA and potency platforms established by UnicoCell's research and development team, the best stem cell characteristics and bioactivity of adipose stem cells are selected from different sources of primary adipose stem cells to establish a cell bank according to the criteria of the International Society for Cellular Therapy (ISCT).
After purification, expansion and cultivation, the cells are cryopreserved at ultra-low temperature and tested and validated according to ICH (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) standards, which constitute Donor Cell Bank, Master Cell Bank, and Working Cell Bank, and are the best cell materials.
The culture media and reagents used in the manufacture of new stem cell products are in compliance with Good Manufacturing Practice (GMP) standards, and no animal derived reagents or serum are used, ensuring the highest level of protection for subjects and users. The new stem cell products produced from UnicoCell's adipose stem cell bank have been validated for clinical safety and efficacy, and are available for the development of various indications in the research units. For more information on allogeneic stem cell bank products, please contact email@example.com